TVTX Q1 2023 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$57M+17.5% YoY

Gross Profit

$52M91.0% margin

Operating Income

-$80M-140.9% margin

Net Income

-$86M-151.5% margin

EPS (Diluted)

$-1.27

QoQ Revenue Growth

+2.0%

Cash Flow

Operating Cash Flow

-$81M

Free Cash Flow

-$109M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$808M

Total Liabilities

$619M

Stockholders' Equity

$189M

Cash & Equivalents

$161M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$57M	$48M	+17.5%
Gross Profit	$52M	$46M	+11.9%
Operating Income	-$80M	-$57M	-40.7%
Net Income	-$86M	-$76M	-13.6%

Revenue Segments

Product

$50M52%

Bile Acid Products

$26M27%

Tiopronin Products

$21M22%